Incredible talk by Nobel laureate David Macmillan David MacMillan on Invention and Discovery in Photocatalysis MacMillan Group! 💡🧪 The lecture hall Department of Chemistry and Pharmacy, Münster was packed to the brim, and his insights were truly inspiring. #Photocatalysis #Chemistry

Enantioselective Synthesis of β-Aminoboronic Acids via Borylalkylation of Enamides | Journal of the American Chemical Society Total Synthesis and Methodology Highlights #Enantioselective #Boroalkylation #Enamides pubs.acs.org/doi/10.1021/ja…

Published today, our fantastic collaboration with Lindsey James group, Brian Raught, and Licht Lab. Thanks to the talented David Nie and John Tabor! nature.com/articles/s4158…

🌟 Exciting news! Enamine Germany is proud to join the MC4DD consortium, led by TU Darmstadt. Together, we're tackling the challenges of macrocycle drug discovery to advance treatments for cancer, depression, and more. Stay tuned for groundbreaking developments! 🧬💊 #MC4DD

#BorschEvent: In late July, the Enamine Germany team came together for a large-scale Ukrainian #Borsch preparation! It was an amazing collaboration between cooking pros and enthusiasts, resulting in a delicious outcome! Check out our video summary & reach out for the recipe)

Wanna insert functionalized carbon atoms into a heterocycle❓🤔 Check out 👉our latest paper in ACS Catalysis for an innovative method to achieve skeletal editing with new reagent Cl-DADO!" pubs.acs.org/doi/10.1021/ac…

This week, Ivan Kondratov will represent Enamine Germany at the #Frankfurt Cancer Conference. Joining leading cancer researchers, junior scientists, and clinical oncologists, this three-day event focuses on "Targeting the tumor-host interface." #CancerResearch #EnamineGermany

Targeted Protein Localization by Covalent 14–3–3 Recruitment dlvr.it/TCVVQX

Selective Covalent Inhibiting JNK3 by Small Molecules for Parkinson's Diseases dlvr.it/TDQ5zm

An allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes dlvr.it/TDdBNg

Why Are VAV1 Degraders Such a Big Deal? Earlier this week, Novartis signed a deal for $150M upfront, up to $2.1B, with Monte Rosa Therapeutics. Drug Hunter scientists highlighted VAV1 patents earlier in the year and noted this program from a conference this summer (see link).

Targeting Cancer: A New Era in Cancer Therapy through Immune Fitness Modulation and KRAS Degradation | ACS Medicinal Chemistry Letters pubs.acs.org/doi/10.1021/ac…

An engineered cereblon optimized for high throughput screening and molecular glue discovery: Chemistry & Biology Ivan Đikić cell.com/cell-chemical-…

PROTACs coupled with oligonucleotides to tackle the undruggable tandfonline.com/doi/full/10.10…

A Medicinal Chemistry Perspective on Protein Tyrosine Phosphatase Nonreceptor Type 2 in Tumor Immunology | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

Our favourite E3 ligase adapter Cereblon is in the spotlight with our newest review by Wenqing! Check it out now and learn about the various chemical biology efforts to understand and explore CRBN activity 🥳🫶⭐️ pubs.acs.org/doi/full/10.10…

I am delighted to share the story that we've been crafting at the Centre for Targeted Protein Degradation in collaboration with Tocris Bioscience Bio-Techne for the last to years! We're thrilled to present BromoCatch - a self-labeling tag platform for protein analysis and manipulation. biorxiv.org/content/10.110…

Happy to see our review out now in Nature Reviews Cancer was fun to co-create this piece with Matthias Valentina and Georg. we aimed to be as contemporary in coverage and forward-looking in outlook on protein degraders mechanisms and cancer therapeutics. nature.com/articles/s4156…

Cereblon (and its buddy, the cyclic imide) is Once Again in the spotlight! Excited to share the lab's latest pub, highlighting the effects of cyclic imide stereoisomers on CRBN activity! 🥳✨ Congrats to Yuka, Saki, and all the authors 🫶 pubs.rsc.org/en/content/art…